A venture capital firm based in St. Louis, Missouri, prefers to make growth-stage, equity investments in a variety of sectors, including the life sciences, typically in the $2M-$10M range. The firm prefers to lead rounds, but will also syndicate deals. The firm’s first fund closed late in 2015, and is targeting between 3 and 5 investments per year, focusing on the Midwestern United States. However, this includes all states except for those in the North East and those on the West Coast.

Within the Life Science space, the firm is primarily interested in data-driven, connected medical devices and diagnostics as well as any technology that improves drug adherence (mobile apps, devices, etc.). The firm has deep domain experience in IT and is therefore very interested in healthcare IT, such as enterprise software solutions. In addition, life science tools are also an area of interest. The firm is open to all sectors within the life sciences, with the exception of therapeutics, and requires that the product is already FDA approved or is exempt from regulatory approval.

The firm prefers to work with experienced management teams and serial entrepreneurs, however the firm is open to working with first-time entrepreneurs. The firm prefers to lead rounds and requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel network founded in 2006 and based in Illinois looks to make seed and venture investments generally ranging from $200K to $2M. The group prefers to invest in companies with pre-money valuations of less than $5 million. While the firm prefers to invest in the Midwestern US they are also open to investing as a member of a syndicate in other regions of the United States.

In the life science space, the group is currently interested in companies working with medical technology, healthcare IT and healthcare services/analytics. In terms of healthcare IT, companies with a B2B or B2C (including wearables) focus are both of interest. The group does not invest in drug development/biopharma companies. The group is looking for companies with Class I and II devices that have a defined 510k regulatory pathway with a clear route to commercialization. The group is open to all indication types within this area, prefers company with the potential to reach commercialization in 6-12 months.

The group is looking for privately held companies with experienced management teams, and looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over US$4.5 billion. The firm is current investing from its newest US$100 million and RMB 1 billion funds that are set to close in 2016. Typical equity allocations range from US$2-6 million in an early stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, US, and EU.

The firm invests across various sectors in life sciences. In pharmaceuticals, the firm is looking for innovative assets in the pre-clinical phase and is open to both small molecules and biologics. The firm focuses on diseases with large market potential such as oncology and cardiovascular conditions. In MedTech, the firm is looking for concept stage or post-prototype products that have large market potential and high entry battier.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angel; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of joint venture and strategic partnership in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Texas and committed to enabling healthcare innovation is currently investing out of its latest fund of $200 million. The firm typically makes initial, equity investments of $10M, with the possibility to allocate up to $35M over the life of the investment.

The firm is currently most interested in the medtech and healthcare IT space, specifically IT-enabled healthcare devices and services. The firm is not interested in traditional medical devices without a software/data-driven component. The firm is indication agnostic, but has particular interest in neurology, cardiology, pulmonology, hearing, and wound care.

The firm seeks to invest in revenue-generating companies with a minimum of $2M-$3M in revenues, although there are no EBIDTA requirements and it is not required that the company be cash-flow positive. The firm will also look at pre-revenue companies on a secondary basis, with the caveat being that there is a clear line of sight to revenue generation. The firm only invests in U.S.-based companies with clinical data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2006 with offices across China and in the US has invested in nearly 50 healthcare companies across all sectors of life sciences from pharmaceuticals and medical devices to healthcare IT and diagnostics. The firm typically leads investments, though is also open to co-investing. The firm typically makes equity investments ranging from $1-$35 million, and currently has $1.7 billion in total assets under management, with their latest fund raised in Feb. 2016 at $648 million. The firm seeks to make 20-30 new investments within the next year, with a geographical focus in China. The firm is open to opportunities in the US, as the firm recently closed deals in Boston, San Francisco, and Los Angeles.

The firm is open to all sectors and subsectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is generally most interested in technology that address a large unmet need that may be in a crowded disease market but with an innovative strategy (i.e. hitting new targets). The firm is not particularly interested in orphan and rare diseases. The firm mostly invests in 510K devices due to its faster turnaround, but will also invest in devices in the PMA pathway depending on its stage. In therapeutics, the firm is interested in all subsectors including small molecule, biologics, cell therapy, and biosimilars. The firm invests in therapeutics that are past the pre-clinical stage at Phase I to on the market, as well as medical devices that are either at the clinical stage or on the market. The firm’s US branch is particularly more open to earlier stage investments, including innovative seed funding, while the China headquarters is more interested in clinical, late-stage technology. The firm is also interested in lab equipment and drug development enabling technologies, and is open to all indications.

The firm prefers a company with a strong management team with experience in the space. The firm will help the company fill spaces in the team if necessary, and will typically take a board seat after an investment. The US branch will mark technology with a China angle as priority for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based pharmaceutical company is looking for any potential drug candidates that align with the company’s strategy. The firm is seeking to strengthen its R&D/manufacturing capability and portfolio/pipeline and is open to all kinds of collaboration models, including straight licensing, co-development, contract selling, equity investment, and M&A. The company is currently looking for assets globally with a focus on the US and Europe.

The firm is interested in mature or generic products in the following areas: Oncology, Neurology, Cardiovascular & Cerebrovascular, Rheumatology and Inflammation, Respiratory Diseases, Infectious Diseases (except HIV), and Pediatric Diseases (except rare disease). Early stage products or platform technology with high potential or clear differentiation will also be considered. In addition, the firm is exploring emerging areas in oncology, such as immunotherapy and cell therapy. In medical technology, the firm is interested in liquid biopsy, cancer diagnostics, and next generation sequencing, and would consider in-development and products.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US and Europe, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen fund established by a family office in Asia is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in local-based businesses and co-invest in businesses overseas. The fund is currently focused on new opportunities in Greater China and Southeast Asia, while they are also interested in US, Canada, and EU-based companies with a China angle.

Currently, the firm is interested in cutting edge, innovative therapeutic and platform technologies in cancer, CNS, and chronic diseases. The fund considers all stages from preclinical through pre-IPO. The fund also considers a broad range of technologies including medical devices, diagnostics, healthcare services, and nutraceuticals. In medical devices, the fund is open to all indications and prefers later stage projects with proof of concept.

The firm is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund prefers to work with Greater China-based companies or foreign businesses that are seeking to enter the Greater China market. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com